RUNX1 and myeloid neoplasm: Moreover, they found mutations in known-CHIP-associated genes, including DNMT3A and TET2, in 22% of preleukemic RUNX1-FPD patients and 40% of patients with myeloid malignancy [36], which is more frequently than within the general population [79].